These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28240991)

  • 1. Long-term treatment with NAO in acute coronary syndromes: rationale and clinical data.
    Lettino M
    J Cardiovasc Med (Hagerstown); 2017 Jan; 18 Suppl 1():e129-e133. PubMed ID: 28240991
    [No Abstract]   [Full Text] [Related]  

  • 2. [New Anticoagulants in the Treatment of Patients With Recent Acute Coronary Syndrome. Place of Rivaroxaban].
    Hirmanov VN
    Kardiologiia; 2015; 55(6):98-104. PubMed ID: 26625526
    [No Abstract]   [Full Text] [Related]  

  • 3. Rivaroxaban in acute coronary syndromes--is it prime time?
    Asrar ul Haq M; van Gaal WJ
    Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):649-58. PubMed ID: 24746010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
    Eriksson BI; Quinlan DJ; Eikelboom JW
    Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New anticoagulants: moving on from scientific results to clinical implementation.
    Eerenberg ES; van Es J; Sijpkens MK; Büller HR; Kamphuisen PW
    Ann Med; 2011 Dec; 43(8):606-16. PubMed ID: 21864021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into direct anticoagulants.
    Saad E; Dally N
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):492-8. PubMed ID: 25828968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct oral anticoagulants: to switch or not to switch?
    Lugthart S; Leebeek FW
    Neth J Med; 2015 Oct; 73(8):359-61. PubMed ID: 26478544
    [No Abstract]   [Full Text] [Related]  

  • 8. Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis.
    Schurgers LJ; Spronk HM
    Thromb Haemost; 2014 Nov; 112(5):909-17. PubMed ID: 25298033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban in acute coronary syndromes.
    Karthikeyan G; Eikelboom JW
    Cardiovasc Ther; 2011 Oct; 29(5):285-90. PubMed ID: 20553278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
    Meddahi S; Samama MM
    J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor Xa and thrombin as targets for new oral anticoagulants.
    Weitz JI
    Thromb Res; 2011 Jan; 127 Suppl 2():S5-S12. PubMed ID: 21193114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of venous thromboembolism: duration and new options.
    Huisman MV
    Hematol J; 2004; 5 Suppl 3():S24-8. PubMed ID: 15190273
    [No Abstract]   [Full Text] [Related]  

  • 13. Anticoagulant agents in acute coronary syndromes.
    Sakhuja R; Yeh RW; Bhatt DL
    Curr Probl Cardiol; 2011 Apr; 36(4):127-68. PubMed ID: 21586352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New antithrombotic agents in acute coronary syndromes.
    Moser M; Bode C
    Curr Opin Cardiol; 2009 Jul; 24(4):313-7. PubMed ID: 19395952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.
    McCarty D; Robinson A
    Ther Adv Cardiovasc Dis; 2016 Feb; 10(1):37-49. PubMed ID: 26378211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism.
    Sciascia S; Breen K; Hunt BJ
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):476-7. PubMed ID: 25923780
    [No Abstract]   [Full Text] [Related]  

  • 18. Will warfarin ever be replaced?
    Ruff CT; Braunwald E
    J Cardiovasc Pharmacol Ther; 2010 Sep; 15(3):210-9. PubMed ID: 20484119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis.
    Bassand JP
    EuroIntervention; 2014 Mar; 9(11):1333-41. PubMed ID: 24650773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Betrixaban - the next direct factor Xa inhibitor?
    Thoenes M; Minguet J; Bramlage K; Bramlage P; Ferrero C
    Expert Rev Hematol; 2016 Dec; 9(12):1111-1117. PubMed ID: 27809616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.